What biomarker tests are recommended for Leukemia

Biomarker and Genetic Testing for Leukemia

Biomarker and genetic testing is a crucial part of leukemia diagnosis and treatment planning. These tests look for specific changes in your leukemia cells that help doctors understand your disease and choose the best treatment for you.

Why Biomarker Testing Matters

According to the NCCN Guidelines for Patients: Acute Myeloid Leukemia, biomarker and genetic tests serve three important purposes:

1. Learn about your leukemia subtype - Leukemia comes in many forms, and identifying which type you have is essential
2. Target treatment - Certain mutations respond to specific therapies
3. Determine prognosis - These tests help predict how your leukemia might progress

Key Tests Recommended

For Acute Myeloid Leukemia (AML)

The NCCN Guidelines recommend several mutation testing methods:

Karyotype (Cytogenetics)

• Takes a "picture" of your chromosomes to look for extra, missing, rearranged, or abnormal pieces
• Requires growing cells from a bone marrow or blood sample
• Shows large chromosomal changes

Fluorescence In Situ Hybridization (FISH)

• Uses special dyes (called probes) that attach to DNA pieces
• Can detect smaller changes that karyotype might miss
• Can be performed on bone marrow or blood samples
• Only looks for known, specific changes

Next-Generation Sequencing (NGS)

• Reads your DNA in detailed ways to find gene mutations
• More sensitive than other methods—can find 1 abnormal cell among 100,000 normal cells
• Catches mutations other tests might miss

Polymerase Chain Reaction (PCR)

• Makes millions of copies of your DNA to detect mutations
• Very sensitive for finding specific genetic changes
• Real-time PCR (RT-PCR) is especially useful for tracking treatment response

For Chronic Myeloid Leukemia (CML)

According to the NCCN Guidelines for Patients: Chronic Myeloid Leukemia, the key test is:

BCR::ABL1 Testing (qPCR using IS)

• Detects the specific fusion gene that causes CML
• The BCR::ABL1 gene is the hallmark of CML—if you don't have it, you don't have CML
• Used both for diagnosis and to monitor treatment response

Common Genetic Changes Tested

Your care team may look for specific mutations, including:

• Gene rearrangements - When parts of genes switch places (like PML::RARA in acute promyelocytic leukemia)
• Deletions - When part of a chromosome or gene is missing (like del(5q))
• Translocations - When pieces of different chromosomes swap places (like t(8;21))
• Point mutations - When a small part of a gene is changed
• FLT3 mutations - Affect how aggressive your leukemia might be

Additional Testing

Immunophenotyping

• Uses antibodies to detect biomarkers (proteins) on the surface of white blood cells
• Helps identify which type of leukemia cells are present
• Certain biomarkers can be targeted with specific treatments

Leukemia Predisposition Syndrome Testing

• A skin punch biopsy may be done to check if you inherited genes that increase leukemia risk
• This is different from testing the leukemia cells themselves
• Important because it can affect how your body responds to treatment

What to Expect

According to NCCN Guidelines:

• Testing takes time—it might take weeks for all results to come in
• Samples come from bone marrow aspirate/biopsy or blood tests
• A pathologist (expert in analyzing cells) reviews your samples
• Results guide your specific treatment plan

Questions to Ask Your Care Team

1. What specific biomarkers or genetic mutations were found in my leukemia cells?
2. What do these mutations mean for my treatment options?
3. How will these results affect my prognosis?
4. Will these tests be repeated during or after treatment to monitor my response?
5. Are there any clinical trials available based on my specific mutations?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.